National Institutes Of Health

Nearly a quarter of patients, 23.7%, treated with adoptive cell transfer tumor-infiltrating lymphocytes for metastatic melanoma have experienced complete and durable responses, according to data presented at ASCO Annual Meeting.

Use of the word “cancer” to describe low-risk malignant neoplasms influenced patient treatment preference regardless of risks or prognosis, according to study results published in JAMA Oncology.

Reductions in lung cancer mortality with low-dose CT screening vs. chest X-ray among participants in the National Lung Screening Trial have been sustained over extended follow-up, according to results of an updated analysis of the trial published in Journal of Thoracic Oncology.

Clinically indicated dose reductions or interruptions of ibrutinib did not appear to impact long-term outcomes among patients with chronic lymphocytic leukemia, according to results of a phase 2 prospective study published in Blood.

A transcatheter procedure performed immediately before transcatheter aortic valve replacement was feasible and safe in patients with severe native or bioprosthetic aortic valve disease who were at high surgical risk, according to a study published in JACC: Cardiovascular Interventions.

CHICAGO — The Conquer Cancer Foundation of ASCO presented ASCO Annual Meeting Merit Awards to more than 100 oncology professionals.

CHICAGO — Rituximab administered concurrently with cladribine as first-line treatment of hairy cell leukemia appeared to induce more durable complete responses with no minimal residual disease compared with delayed rituximab administration, according to results of a phase 2 randomized study presented at ASCO Annual Meeting.

Rapid increases in the incidence of HPV-related oropharynx cancer among young white men across the United States over the past several decades appeared to have slowed, according to results of a retrospective study published in Journal of Clinical Oncology.

PHILADELPHIA — Effectively treating solid epithelial cancers will require targeting a patient’s somatic cancer mutations, leading to highly complex, individualized treatments, according to Steven A. Rosenberg, MD, PhD, chief of surgery at the NCI.

Increasing the dose of total body irradiation to 400 cGy from 200 cGy greatly reduced graft failure among patients with sickle cell disease or beta-thalassemia who received a haploidentical bone marrow transplant with post-transplantation cyclophosphamide, according to results of a phase 2 prospective study published in The Lancet Haematology.